Editorial Commentary: Clinical Significance of HIV Subtype Variability in Regard to Treatment Outcome.

about

No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom.

P2860

Q37365060-936A994E-C9CA-4A80-AE99-2586704E0A08

P2860

Editorial Commentary: Clinical Significance of HIV Subtype Variability in Regard to Treatment Outcome.

Item

http://www.wikidata.org/entity/Q51060522

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Editorial Commentary: Clinical ...... n Regard to Treatment Outcome.

@en

Editorial Commentary: Clinical ...... n Regard to Treatment Outcome.

@nl

type

Item

label

Editorial Commentary: Clinical ...... n Regard to Treatment Outcome.

@en

Editorial Commentary: Clinical ...... n Regard to Treatment Outcome.

@nl

prefLabel

Editorial Commentary: Clinical ...... n Regard to Treatment Outcome.

@en

Editorial Commentary: Clinical ...... n Regard to Treatment Outcome.

@nl

P1476

Editorial Commentary: Clinical ...... n Regard to Treatment Outcome.

@en

P2093

Mark A Wainberg

http://www.w3.org/2001/XMLSchema#string

P2860

Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections.

High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis

High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen

In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.

A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.

HIV-1 subtype as a determinant of disease progression.

P304

1550-1551

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1093/CID/CIV107

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25681379

http://www.w3.org/2001/XMLSchema#string

Editorial Commentary: Clinical Significance of HIV Subtype Variability in Regard to Treatment Outcome.

about

P2860

P2860

Editorial Commentary: Clinical Significance of HIV Subtype Variability in Regard to Treatment Outcome.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698